/ 2 items

#ALT↓

Featured/ ETNB/ 09/19/2025 · 8:35 AM

Pharma Giant Roche Buys 89bio for up to $3.5 Billion to Fight Fatty Liver Disease

Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.

ALT/ 08/27/2025 · 4:15 PM

FDA Breakthrough: New Non-Invasive Biomarker to Revolutionize MASH Drug Development

The FDA accepted non-invasive Liver Stiffness Measurement as a surrogate endpoint for MASH clinical trials, replacing biopsies. This key decision accelerates MASH drug development by enabling safer monitoring, speeding recruitment, and predicting patient outcomes.